Hepatocellular carcinoma(HCC)is the fourth leading cause of cancer death in the world,and its prognosis is poor.Most HCC patients are diagnosed at an advance stage and are not candidates for surgery.Even if the early-stage tumor is resected,HCC patients tend to relapse within 5 years.In the era of targeted therapy and immunotherapy,neoadjuvant therapy has gained increasing attention and recommendation.For HCC patients with high recurrence risk,neoadjuvant therapy refers to preoperative local or systemic therapy,which can reduce tumor burden,remove tiny lesions,widen surgical margin,and reduce the recurrence risk.However,if the neoadjuvant therapy is not optimal,the timing of surgery will be delayed,resulting in disease progression or even loss of the chance for surgery.This article reviews the research progress of neoadjuvant therapy for HCC.

Objective To assess the effects of two different managements of typeⅢsupracondyla humeral fractures in children: open reduction vs closed reduction and pinning. Methods Relevant articles were identified by using several database (Pubmed Medline, EMbase, cochranelibrary, CBM, CNKI, wanfang data). Control studies comparing closed reduction with percutaneous pinning and open reduction with pinning were analyzed.Results There was no significant difference in the carrying angle according to criteria of Flynn(OR=0.92,P=0.760).There was no significant difference in the functional results according to criteria of Flynn(OR=1.77, P=0.557).There was no significant difference in the ulnar nerve injury(OR=1.10,P=0.332).However, there was a obvious tendency to excellent and good results in the closed reduction group. Conclusions We recommend that closed reduction with percutaneous pinning should be performed first unless some special circumstances are present, for example:complex fractures and failed closed reduction.